The enhanced-sensitivity Trofile assay (TF-ES; Monogram Biosciences) was used to retest coreceptor tropism samples from 4 different cohorts of HIV-1-infected patients. Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts.
Bibliographical noteFunding Information:
Financial Support. The CPCRA and INSIGHT networks are funded by the National Institutes of Health (U01 AI-42170, U01 AI-46362, U01 AI-68641). The ACTG is funded by the National Institutes of Health (U01 AI-68636 and AI-68634 [Statistical and Data Analysis Center]). Other grants that funded coauthors include K23 AI55038 (to T.J.W.), K24 AI51966 (to R.M.G.), AI-69419 (Cornell Clinical Trials Unit), RR024996 (Cornell CTSC), and AI-46381 (Miriam Hospital Clinical Research Site). Monogram Biosciences received an SBIR grant from the National Institutes of Health (R44AI050321).
Potential conflicts of interest. T.J.W. has served as a paid consultant to Pfizer and Quest Diagnostics. M.B.G. receives grant support from Monogram. G.S. has received honoraria from ViiV Healthcare and Boehringer-Ingelheim and has served as a paid consultant to Tobira Pharmaceuticals. Z.S. has served as a paid consultant to Pfizer and Quest Diagnostics. J.H. and D.C. are employed by and have stock in Pfizer, Inc. J.D.R. and E.C.are employed by Monogram Biosciences. R.M.G. served as an adhoc consultant to ViiV Pharmaceuticals. R.L., E.S.C., and J.S. have no conflicts to report.